Opinion: Emergency Use Authorizations Are a Threat to Science
As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.
Opinion: Emergency Use Authorizations Are a Threat to Science
Opinion: Emergency Use Authorizations Are a Threat to Science
As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.
As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.
Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.
After years of stalling, the agency says it plans to provide notice on pending applications from growers—but only after it establishes new regulations for suppliers.
Two coauthors of a new study discuss their findings about nearly 170 facilities in the southwestern US selling unproven therapies—and what should be done about them.
In determining that the illnesses came about from exposure to glyphosate in Roundup, a California jury delivers the biggest loss so far to the herbicide manufacturer in lawsuits about the product.
FDA researchers report that multiple active ingredients wind up in users’ bloodstream and recommend toxicology testing to investigate the clinical significance of the findings.
Conceived as a way to resolve differences between government regulators and academics over the chemical’s effects, the CLARITY-BPA collaboration instead highlights divisions.